Colorado state Rep. Dominique Jackson of Aurora said Monday she’s dropping a bill on prescription drug transparency that also includes a controversial provision to send rebates for high-cost prescription drugs to consumers. 

As first reported by the Denver Business Journal, House Bill 1296 was awaiting action from the House Appropriations Committee Monday when Jackson made the decision. Jackson told Colorado Politics she wants to continue working on the measure to get a policy with more buy-in from some of its stakeholders — with the legislative session ending Friday.

> RELATED: Insurers cry foul over bill on prescription drug costs

Jackson, D-Aurora, knows the problem of high-cost prescription drugs first-hand. She is being treated for an auto-immune disorder, and told the House Health & Insurance Committee on April 16 that one of her medications is going up in price from $25 for a 90-day supply to $1,550.17 for that same 90-day supply.

It’s not new medications that are driving up the cost of prescriptions, she explained. It’s medications that are already on the market.

The bill would require health insurers, prescription drug manufacturers, pharmacy benefit management (PBM) firms, and nonprofit organizations to report certain information about the costs of prescription drugs to the commissioner of insurance.

It also would require the state insurance commissioner to analyze the information and submit a report regarding the effects of prescription drug costs on health insurance premiums.

A third provision would ban PBM firms from retroactively reducing payments to pharmacies. And it would require health insurance plans and PBMs to send rebates for high-cost prescription drugs directly to consumers.

The bill’s section on rebates caused a lot of angst for health care plans and PBMs.

Jackson acknowledged that there may not be enough time in the few days left in the 2019 session to get the bill all the way through the process.

“I think, like many things, we’re running out of time,” Jackson told Colorado Politics Monday

But she added: “I’m very committed to making sure that we have the right policy. So I’m more than happy to have more eyeballs on it and work with the insurance carriers, drug manufacturers, PBMs, nonprofits and the governor’s office and the Division of Insurance and everyone involved to make sure that we’re all at the table together. We will sure we have the best policy that we can.”

Whether that means agreement on the bill’s biggest sticking point — the rebates — is still to be decided.

“I am under no illusions that they’ll come to a big Kumbaya,” she said. “But I want to afford everyone more opportunity to come to the table.”